Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition

BACKGROUND: Inflammatory mediators, including acute phase reactants and cytokines, have been reported to be associated with clinical efficacy in patients with melanoma and other cancers receiving immune checkpoint inhibitors (ICI). Analyses of patient sera from three large phase II/III randomized IC...

Descripción completa

Detalles Bibliográficos
Autores principales: Laino, Andressa S, Woods, David, Vassallo, Melinda, Qian, Xiaozhong, Tang, Hao, Wind-Rotolo, Megan, Weber, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312339/
https://www.ncbi.nlm.nih.gov/pubmed/32581042
http://dx.doi.org/10.1136/jitc-2020-000842

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312339/
https://www.ncbi.nlm.nih.gov/pubmed/32581042
http://dx.doi.org/10.1136/jitc-2020-000842

Ejemplares similares